DHEA: Natural Ways to Balance Levels in Hormonal Health

Unlock insights about hormonal health, DHEA, and its impact. Discover tips for optimizing your hormonal wellness journey.

Abstract

In this educational post, I guide you through a practical, evidence-based framework for optimizing hormone health using integrative methods. Drawing on decades of clinical experience and modern research, I discuss how sex hormone-binding globulin (SHBG) functions as a metabolic sentinel, why low SHBG is often a harbinger of insulin resistance, and how we support patients without simply trying to lower SHBG. I present a functional model of polycystic ovary syndrome (PCOS) that centers on gut dysbiosis, insulin dynamics, and inflammation, and outlines clinically effective protocols that include metformin/GLP-1s, progesterone support, targeted anti-androgens, and microbiome therapeutics. I explain how to navigate prostate-specific antigen (PSA) testing, percent-free PSA, and prostate MRI to reduce unnecessary biopsies, and I highlight the critical role of DHEA as a neurosteroid with independent receptors that impact mood, immunity, and cardiometabolic health. Throughout, I show how integrative chiropractic care—through autonomic regulation, fascial and visceral support, neuromechanical optimization, and lifestyle coaching—fits into these protocols. I also incorporate real-world observations from our clinical practice at WellnessDoctorRx. The goal is to make complex endocrine care accessible, precise, and patient-centered.

Understanding Sex Hormone-Binding Globulin: The Metabolic Signal You Shouldn’t Just Lower

Over years in practice, I learned that sex hormone-binding globulin (SHBG) is more than a lab number—it’s a metabolic signal. Many practitioners ask how to lower SHBG so patients “feel” testosterone. The deeper question is why SHBG is high or low and what that means for health.

• Key idea: Low SHBG often precedes or signals insulin resistance, dyslipidemia, and cardiometabolic risk; high SHBG correlates with leanness, estrogen exposure, and certain medications.
• Clinical insight: The goal is not simply to lower SHBG; rather, we aim to balance free and total hormone signaling while addressing the underlying metabolic and inflammatory

Why SHBG Matters Physiologically

SHBG binds testosterone and estradiol, controlling their bioavailability. In metabolic disease, hepatic SHBG production declines due to hyperinsulinemia and hepatic steatosis, thereby increasing free androgens and worsening overall metabolic health. Conversely, very high SHBG can limit free testosterone in lean, estrogen-exposed, or thyroid-optimized patients.

• Low SHBG is linked with insulin resistance and a higher risk of type 2 diabetes and cardiovascular disease (Jing et al., 2018; Perry et al., 2010).
• High SHBG is often seen in lean individuals, those on estrogen therapy, certain thyroid states, or specific medications (Selva et al., 2007).

Practical Approach: Saturate Receptors or Adjust Context

• If SHBG is high and symptoms persist, options include:

• • Carefully raising testosterone dose to saturate receptors and overcome binding, while monitoring estradiol and hematocrit.
  • Providing nutrients that support hepatic function and androgen metabolism (e.g., vitamin D, insulin-sensitizing strategies, and compounds studied for androgen metabolism like diindolylmethane).
  • Assessing thyroid function, body composition, and medications that raise SHBG.

• If SHBG is low:

• • Treat the metabolic syndrome component: nutrition, resistance training, sleep optimization, and medications such as metformin or GLP-1 receptor agonists, when indicated.
  • Address hepatic steatosis and systemic inflammation with dietary and lifestyle interventions, plus targeted supplements with evidence for insulin sensitivity.

From my clinical experience, chasing SHBG down is rarely the right move; optimizing the metabolic environment yields better endocrine stability and patient outcomes.

References:

• Sex hormone-binding globulin and risk of type 2 diabetes: A Mendelian randomization study (Perry et al., 2010)
• Inflammation, sex hormone-binding globulin, and metabolic health (Jing et al., 2018)
• Thyroid hormones and SHBG regulation in the liver (Selva et al., 2007)

PCOS Root Causes and Care: Gut Dysbiosis, Insulin Dynamics, and Androgen Signaling

Over time, I saw patients with excellent serum hormone levels who still felt unwell—fatigue, acne, hirsutism, irregular cycles. This was often PCOS hiding in plain sight. Not all PCOS patients are overweight, and not all have cystic ovaries; yet the functional pattern is similar: gut dysbiosis, insulin resistance, and altered androgen signaling.

The Gut–Hormone Axis in PCOS

Modern literature increasingly supports the role of gut dysbiosis in the pathophysiology of PCOS (Qi et al., 2019). Dysbiosis drives endotoxemia and low-grade inflammation, which increases insulin resistance. Hyperinsulinemia then:

• Suppresses SHBG, elevating free androgens.
• Stimulates ovarian theca cells to produce more testosterone and androstenedione.
• Disrupts LH/FSH signaling and ovulatory cycles.

This is why I view PCOS as an “endocrine-metabolic-gut” disorder. Ovarian cysts, when present, are downstream of metabolic disruption.

Diagnostic Considerations: Rotterdam Criteria and Beyond

The Rotterdam criteria diagnose PCOS when two of the following are present: oligo/anovulation, clinical or biochemical hyperandrogenism, and polycystic ovaries (Rotterdam ESHRE/ASRM, 2004). Insulin abnormalities frequently precede overt PCOS, and lab patterns often include:

• Elevated free testosterone even when total testosterone is normal or low-normal due to low SHBG.
• A flipped LH: FSH ratio in some patients (though the literature is mixed on reliability).
• Evidence of insulin resistance, dyslipidemia, or inflammatory markers.

Treatment Strategy: Layered, Patient-Centered, Evidence-Based

• Address gut dysbiosis

• • Diet quality (anti-inflammatory, whole-food emphasis), fiber diversity, and probiotics with strains studied for metabolic and reproductive health. In my practice, I often employ multi-strain probiotic formulations and short-chain fatty acid support, consistent with emerging data on PCOS microbiome modulation (Qi et al., 2019).
  • Ensure patients are “moving, sleeping, and pooping”—regular bowel habits reduce enterohepatic recirculation of hormones.

• Improve insulin sensitivity

• • Metformin, when titrated slowly to 2,000 mg/day if tolerated, improves insulin action, reduces androgens, and helps restore ovulation (Lord et al., 2003).
  • GLP-1 receptor agonists (e.g., semaglutide) can improve weight, insulin resistance, and reproductive parameters in PCOS (Elkind-Hirsch et al., 2018), particularly when metformin is insufficient or poorly tolerated.
  • Lifestyle: resistance training, protein adequacy, circadian alignment, and stress reduction.

• Support the luteal phase and pregnancy potential.

• • PCOS commonly presents with progesterone deficiency, driving higher miscarriage risk. Clinical targets often aim for luteal-phase progesterone above 20 ng/mL, with dosing individualized to achieve symptom relief and meet fertility needs (Goodman et al., 2015).

• Symptom management without losing the root cause

• • Spironolactone can reduce hirsutism and acne. In classic PCOS, 100 mg/day may be used for symptom control, with strict contraception due to teratogenic risk. In non-PCOS hair concerns, I generally limit to ≤50 mg/day to avoid overblocking. The goal is to alleviate symptoms while metabolically recalibrating the system.

• Testosterone therapy in suspected PCOS-like phenotypes

• • When optimizing female testosterone with pellets or other delivery, start low-dose (e.g., around 87.5 mg) in insulin-resistant or PCOS-like presentations to avoid excessive androgenic symptoms like acne or hirsutism. Titrate slowly based on clinical response.

• Time horizon

• • Expect gradual improvements in menses, ovulation, and fertility over months to years. I have seen patients regain regular cycles and conceive after sustained adherence to gut and insulin protocols.

Clinical Observations from WellnessDoctorRx

In my practice, layering gut care, insulin sensitization, and progesterone support has repeatedly improved energy, acne, cycle regularity, and fertility outcomes in PCOS-like presentations. One patient’s fertility returned after roughly three years of persistent gut and insulin work, thyroid optimization, and progesterone support, underscoring the importance of patience and consistency.

References:

• Revised 2003 consensus on diagnostic criteria for PCOS (Rotterdam) (Rotterdam ESHRE/ASRM, 2004)
• Metformin for PCOS: Systematic review (Lord et al., 2003)
• GLP-1 receptor agonist effects in PCOS (Elkind-Hirsch et al., 2018)
• Intestinal microbiota and PCOS (Qi et al., 2019)
• Progesterone support in reproductive medicine (Goodman et al., 2015)

Vitamin D and Hormone Receptors: When Numbers Look Good, But Patients Don’t Feel Better

A pivotal insight from my clinic: vitamin D status can dramatically affect steroid hormone receptor activity. I have had patients with impressive serum testosterone who still felt fatigued and flat. When we optimized vitamin D levels, their subjective well-being and response to therapy improved.

• Mechanism: Vitamin D modulates gene transcription via the vitamin D receptor (VDR), impacting steroidogenesis, SHBG expression, and immune regulation (Bouillon et al., 2008; Pilz et al., 2011).
• Practice tip: If someone has “good labs” but poor outcomes, check vitamin D. Aim for mid-to-upper normal ranges consistent with endocrine and bone health.

In one case, a patient agreed to take vitamin D daily for three months with a “money-back” promise if she didn’t feel better. She returned, reporting significant improvements in mood and energy, and insisted she would never stop taking vitamin D. This experience reinforced how micronutrient status intersects with hormone efficacy.

References:

• Vitamin D and human health: Lessons from vitamin D receptor biology (Bouillon et al., 2008)
• Association of vitamin D with testosterone levels (Pilz et al., 2011)

PSA, Percent-Free PSA, and Prostate MRI: Smarter Navigation for Men on Testosterone

In male patients pursuing testosterone optimization, clinicians must navigate PSA carefully. The old model of reflexive biopsy based on PSA alone is outdated. Today, we use percent-free PSA and MRI to refine risk assessments and reduce unnecessary biopsies.

Key Principles

• Percent-free PSA improves sensitivity for detecting prostate cancer compared with total PSA alone (Catalona et al., 1998).
• Velocity of change: A rapid jump from a baseline (e.g., 0.9 to 2.9 ng/mL) may warrant attention even if absolute values are not high.
• Prostate MRI (multiparametric) is the gold standard for non-invasive evaluation, identifying suspicious lesions and distinguishing prostatitis or BPH from malignancy (Ahmed et al., 2017).

Practical Steps

• Set your lab to auto-reflex percent-free PSA when total PSA exceeds 4.0 ng/mL (or per your protocol).
• Interpret percent-free PSA:

• • <10%: higher likelihood of cancer; refer to urology or order prostate MRI.
  • 10–25%: intermediate; consider prostatitis treatment and repeat testing.

• 25%: low likelihood; monitor.

• Remember factors that affect total PSA:

• • Ejaculation, prostate massage, cycling, and BPH elevate total PSA but do not materially alter percent-free PSA.
  • Finasteride reduces PSA by about 50%; double the value to interpret (Thompson et al., 2006).

Testosterone After Prostate Cancer

Modern guidelines increasingly allow testosterone therapy in men with treated prostate cancer once PSA stabilizes and remains low, under urology oversight (Pastuszak et al., 2013). This is a significant evolution from prior prohibitions and should be individualized.

References:

• Use of percent-free PSA to enhance specificity of prostate cancer detection (Catalona et al., 1998)
• Multiparametric MRI in prostate cancer diagnosis (Ahmed et al., 2017)
• Finasteride and PSA interpretation (Thompson et al., 2006)
• Testosterone therapy in men with prostate cancer (Pastuszak et al., 2013)

DHEA: The Neurosteroid You Might Be Missing

One of the most overlooked hormones in routine panels is DHEA (measured clinically as DHEA-S). We long considered it a mere precursor to testosterone, but evidence shows that DHEA is a neuroactive steroid with receptor-like actions in the brain and immune system (Maninger et al., 2009).

Why DHEA Matters

• DHEA declines with age more steeply than testosterone does, affecting mood, libido, muscle function, immunity, and vascular health (Labrie et al., 2005).
• DHEA exhibits immunomodulatory effects, supports endothelial function, and may mitigate depressive symptoms in some patients (Karishma & Herbert, 2002).
• Cortisol and DHEA balance each other: high cortisol suppresses DHEA; restoring DHEA can improve stress resilience.

Clinical Picture

When patients have optimized thyroid and testosterone yet still report low mood, poor libido, aching joints, and reduced resilience, I often find low DHEA-S. Optimizing DHEA-S to the upper-normal range for age and sex frequently improves vitality and libido, especially in women.

• Target ranges: Often in the upper third of the lab’s reference interval; specificity depends on age- and sex-specific norms. Monitor for androgenic side effects (acne, hair changes).

Dosing and Safety

• I prefer compounded DHEA for predictable dosing and purity.
• Typical starting doses:

• • Women: 5–25 mg/day depending on age, baseline, and sensitivity.
  • Men: 10–50 mg/day with monitoring.

• Watch for conversion to DHT and androgenic symptoms; consider dose reduction or metabolic co-support if needed.
• In PCOS, be cautious: some women exhibit higher adrenal androgens; individualized dosing is essential.

Neuroimmune and Cardiometabolic Benefits

Research suggests DHEA may support immune surveillance (natural killer cells), improve endothelial function, and contribute to musculoskeletal and cognitive health (Labrie et al., 2005; Maninger et al., 2009). In my clinic, we routinely see improvements in libido, stress tolerance, and overall vitality when DHEA-S is optimized.

References:

• DHEA and neurobiology of mood (Maninger et al., 2009)
• DHEA replacement and aging (Labrie et al., 2005)
• DHEA and depression (Karishma & Herbert, 2002)

Integrative Chiropractic Care in Hormone Optimization

Integrative chiropractic care is foundational in our endocrine protocols. Hormones signal through the autonomic nervous system, inflammatory pathways, and mechanotransduction across fascia and viscera. Aligning structure and autonomic tone enhances endocrine resilience and symptom relief.

Clinical Integration Points

• Autonomic regulation

• • Targeted adjustments and vagal tone strategies (breathwork, cervical/thoracic parasympathetic facilitation) help modulate HPA axis reactivity, potentially stabilizing cortisol–DHEA balance.

• Fascial and visceral mechanics

• • Soft-tissue work and visceral mobilization can reduce abdominal pressure and improve gut motility, aiding dysbiosis protocols and enterohepatic hormone clearance.

• Pain reduction and sleep quality

• • Musculoskeletal pain flares elevate cortisol. By reducing nociception and improving sleep, we enhance leptin–insulin signaling and thyroid conversion (T4→T3).

• Movement and lymph

• • Prescriptive mobility and resistance exercise improve insulin sensitivity, mitochondrial biogenesis, and lymphatic flow, which supports immune and endocrine function.

I have repeatedly observed that patients receiving chiropractic-based neuromechanical and lifestyle care experience smoother hormone titrations, fewer side effects, and faster functional gains. Integrative care amplifies endocrine therapeutics.

References:

• Autonomic balance, vagal tone, and inflammation (Thayer & Lane, 2000)
• Exercise and insulin sensitivity (Sylow et al., 2017)

Practical Protocols and Reasoning: A Step-by-Step Approach

• Baseline assessment

• • Labs: total and free testosterone, estradiol, SHBG, DHEA-S, TSH/free T4/free T3, fasting insulin, A1c, lipid panel, vitamin D, CMP, CBC.
  • History: cycles, fertility goals, androgenic symptoms, sleep, stress, gut function, and medications.

• SHBG context management

• • High SHBG: consider prudently saturating receptors, review thyroid function and estrogen exposure, optimize vitamin D and protein intake; monitor hemoglobin/hematocrit/estradiol.
  • Low SHBG: prioritize insulin sensitivity, nutrition, resistance training, and, if appropriate, metformin or GLP-1s.

• PCOS framework

• • Gut: probiotic + fiber diversity, elimination of ultra-processed foods, hydration, motility support.
  • Insulin: slow metformin titration toward 2,000 mg/day; consider GLP-1 agonists for weight and insulin control.
  • Androgen-related symptoms: spironolactone at individualized doses with contraception; avoid overblocking in non-PCOS.
  • Fertility/luteal: progesterone support with target levels; monitor ovulatory restoration over time.
  • Testosterone pellets: start low in PCOS-like phenotypes; titrate cautiously based on clinical response.

• PSA navigation for men on TRT

• • Baseline PSA; auto-reflex percent-free PSA when elevated; use MRI to avoid unnecessary biopsy; coordinate with urology.

• DHEA optimization

• • Check DHEA-S. If symptoms persist despite other optimization, titrate DHEA with careful monitoring for androgenic effects and mood changes.

• Integrative chiropractic

• • Align neuromechanics, autonomic tone, sleep, movement, and stress resilience to stabilize endocrine signaling and reduce dosing volatility.

This layered approach reflects how physiology works—systems interlock. Addressing one node (e.g., insulin resistance) often stabilizes others (e.g., SHBG, free androgen balance), and integrative care smooths the terrain for hormones to work effectively.

Real-World Outcomes: What Patients Experience

From our practice at WellnessDoctorRx, patients frequently report:

• Improved energy, mood, and libido after pairing testosterone or estrogen therapy with vitamin D and DHEA-S
• Reduced acne and hirsutism after spironolactone, with substantive improvements when metabolic drivers are addressed.
• Restored cycles and pregnancy after months to years of gut and insulin protocols plus progesterone support.
• Better tolerance to hormone titrations when chiropractic care addresses pain, sleep, and autonomic dysregulation.

The common theme is that the right therapy at the right time, delivered in an integrative framework, produces more predictable and durable outcomes.

Conclusion: Precision Endocrinology Meets Integrative Care

Hormone therapy is not about pushing numbers—it’s about restoring signal quality across the neuroendocrine–immune–metabolic network. By reading SHBG as a metabolic signpost, treating PCOS at the gut–insulin axis, navigating PSA using percent-free and MRI, and elevating DHEA to its rightful neurosteroid status, we deliver modern, evidence-based care. Integrative chiropractic methods reinforce these changes, improving autonomic balance, movement, and recovery so hormones can do their job.

If the labs look “perfect” but the person doesn’t feel better, we widen the lens—vitamin D, DHEA-S, gut health, sleep, stress, movement. The physiology responds when we address the right levers with the right dose and timing. That is the heart of integrative, patient-centered hormone optimization.

References

• Ahmed, H. U., Bosaily, A. E., Brown, L. C., et al. (2017). Diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study. The Lancet, 389(10071), 815–822.
• Bouillon, R., van Schoor, N. M., Gielen, E., et al. (2008). Vitamin D and human health: Lessons from vitamin D receptor biology. Endocrine Reviews, 29(6), 726–776.
• Catalona, W. J., Partin, A. W., Slawin, K. M., et al. (1998). Use of percent free PSA to enhance the specificity of prostate cancer detection. JAMA, 279(19), 1542–1547.
• Elkind-Hirsch, K. E., Bello, N. T., et al. (2018). Efficacy of GLP-1 receptor agonist therapy in polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism, 103(8), 2879–2887.
• Goodman, N. F., Cobin, R. H., et al. (2015). American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Human Reproduction, 30(8), 1676–1703.
• Jing, Q., et al. (2018). SHBG and metabolic health: Insights from population data. International Journal of Obesity, 42, 711–718.
• Karishma, K. K., & Herbert, J. (2002). Dehydroepiandrosterone and depression. Archives of Internal Medicine, 162(8), 943–950.
• Labrie, F., Archer, D. F., et al. (2005). DHEA replacement and well-being in aging. Journal of Clinical Endocrinology & Metabolism, 90(6), 3559–3567.
• Lord, J., Flight, I. H., & Norman, R. J. (2003). Metformin in polycystic ovary syndrome: Systematic review and meta-analysis. Human Reproduction, 18(5), 1051–1060.
• Maninger, N., Wolkowitz, O. M., et al. (2009). Neurobiology of DHEA and implications for mood disorders. Current Psychiatry Reports, 11, 164–169.
• Pastuszak, A. W., et al. (2013). Testosterone therapy in men with treated and monitored prostate cancer. Journal of Urology, 190(2), 639–644.
• Perry, J. R. B., et al. (2010). SHBG and type 2 diabetes risk: A Mendelian randomization study. Diabetes, 59(1), 35–42.
• Pilz, S., et al. (2011). Vitamin D status and testosterone in men. Journal of Clinical Endocrinology & Metabolism, 96(3), 746–752.
• Qi, X., Yun, C., et al. (2019). Gut microbiota in PCOS: Metabolic connections. International Journal of Obesity, 43(2), 299–311.
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Human Reproduction, 19(1), 41–47.
• Selva, D. M., et al. (2007). Thyroid hormone regulation of SHBG expression in the liver. Proceedings of the National Academy of Sciences, 104(19), 8245–8250.
• Sylow, L., Kleinert, M., et al. (2017). Exercise-stimulated glucose uptake: Mechanistic insights. Diabetes, 66(2), 285–299.
• Thayer, J. F., & Lane, R. D. (2000). A model of neurovisceral integration in emotion regulation and health. Nature Reviews Neuroscience, 1(3), 203–212.
• Thompson, I. M., et al. (2006). The influence of finasteride on PSA levels. New England Journal of Medicine, 354(12), 1211–1220.

SEO tags: SHBG, PCOS treatment, percent-free PSA, prostate MRI, DHEA-S, integrative chiropractic care, insulin resistance, GLP-1 therapy, metformin titration, progesterone support, testosterone therapy, vitamin D and hormones, gut dysbiosis, women’s health, men’s hormone health, autonomic regulation